Connect with us


I’m working to revitalize an Indigenous language and bring it into the future

A scholar works to document local dialect of the Ojibwe language that was spoken by his grandmother.



The author captures threads of a dialect by recording words for "Michipicoten" in an open-air meeting with community elders. John-Paul Chalykoff, CC BY-ND

Language is foundational to Indigenous communities, including my own, and a vital connection to our cultures.

It is well documented how residential schools in Canada and boarding schools in the U.S. devastated Indigenous languages and severed cultural connections. While our languages are in decline, efforts to sustain them are ongoing, and I am taking part in that work.

Language revitalization efforts, both in Canada and the U.S., are opportunities for Indigenous peoples to reclaim their cultural ties. Strategies for revitalizing languages range from language documentation and mentor-apprenticeship programs to immersion language schools. I agree with linguist Nancy Hornberger, who writes that language revitalization is not about bringing a language back but bringing it forward. In other words, making sure it can be used by future generations.

These efforts are ongoing in Indigenous communities across the world, including Anishinaabe. Anishinaabe are primarily situated around the Great Lakes and include the Ojibwe, Odawa and Potawatomi.

I am Ojibwe, a member of Michipicoten First Nation, and my work focuses on documenting the dialect of our region. After teaching at Michigan State University for three years, I accepted a position in 2022 as assistant professor in Anishinaabe Studies at Algoma University and Shingwauk Kinoomaage Gamig in Sault Ste. Marie, Ontario.

Three white teepees on yellow grass with the sunlight behind them.
Michipicoten teepees by Lake Superior. Brianna Beaupré-Carroll, CC BY-ND

A broken link

In my family, for example, my grandmother was our last family member to speak fluent Ojibwe at home. My grandmother – and her parents before her – were relocated to residential schools, where they were punished for speaking their language. That experience and other intergenerational community traumas caused her to eventually lose much of her language fluency. After her grandmother passed away, my grandmother’s primary source of Ojibwe ended, and that was the end of the cultural transmission of language in our family.

This led to a language shift that many families and communities have faced for decades. This shift involved English becoming the primary language in the household. Most of us who want to learn Ojibwe now have to take on the challenge of learning it as a second language.

To help document more of the local variations of Ojibwe language in Michipicoten, I utilize a number of methods to gather vocabulary.

Gathering includes documenting spoken language through audio recordings and their transcriptions as well as recalling the stories behind phrases I’ve been taught. This ongoing work provides the foundation to not only preserve but to create in the language.

Snow-covered roads bordered by small houses and a curved fence line.
A Michipicoten winter sunset. John-Paul Chalykoff, CC BY-ND

Rebuilding Indigenous language

Anishinaabemowin, the Ojibwe language, is spoken by Anishinaabe people from Québec to Alberta and from Michigan to Montana. Given the geographic range of the language, many dialects are spoken, and they are often broadly categorized between east and west.

A map of the United States and Canada, with red dots clustered around the Great Lakes.
Red rings show Anishinaabe communities and areas where an Anishinaabe language is spoken. CJLippert/Wikipedia

They are frequently differentiated by whether short vowels are voiced or unvoiced – like “Anishinaabe” (western) and “Nishnaabe” (eastern). Michipicoten First Nation where I am working to sustain Anishinaabemowin, is most likely part of the north of Lake Superior dialect.

Although endangered, Anishinaabemowin is one of the healthier Indigenous languages in North America. Notably, it is one of three Indigenous languages in Canada, along with Cree and Inuktitut, with good odds of continuing into the next generations.

Anishinaabewakiing, or Anishinaabe territory, lies partly in Canada and partly in the U.S. – so we count Anishinaabemowin speakers in both countries together. Together, there are approximately 30,000 Anishinaabemowin speakers in Canada – which includes Michipicoten – and the U.S.

Family ties to language

Michipicoten is a small Ojibwe community with a population of 1,353 that is close to the northeastern shore of Lake Superior in Ontario, Canada. Nearly 100 people live on the reserve; most are spread out in other towns and cities.

My ongoing work with Michipicoten is to document the local dialect by working with our elders who still know the language. Because there are not many fluent speakers left in the region, it is urgent to document as much as possible.

I am keeping a record of words I remember my grandmother sharing and extending this work with other family and community members.

A fire burning in a circle of rocks under an open-air enclosure.
An elder keeps the fire stoked at Michipicoten. John-Paul Chalykoff, CC BY-ND

I recall my grandmother sharing little stories about words. One of my favorites was the time when we were sitting around the dinner table and she remembered what the old ones would call beans: “boogijimin” – the farting fruit. Everyone had a good laugh.

This summer, I spent some time with Michipicoten elders William and Myrtle Swanson, who shared stories about Ojibwe nicknames from their childhood, sayings they remember, as well as a song from their youth.

Each word and sound is a treasure to preserve.

Breathing life into words

I sometimes think about how I will never fully sound like my family who spoke before me.

Still, I am committed to gathering as much as I can, collecting whatever pieces I can, and trying to put together a puzzle I know I can’t fully complete.

As the respected Ojibwe language instructor Patricia Ningewance says, “Our language exists today because our ancestors survived great hardships. The dialect we learn is the remainder of that time. Let’s honor the ancestors by learning the language they left behind for us to speak.”

I was an elected councilor of Michipicoten First Nation for two terms, between 2017/2021.

Read More

Continue Reading


Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…



To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading


Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….



Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 


About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. 

Read More

Continue Reading


Another country is getting ready to launch a visa for digital nomads

Early reports are saying Japan will soon have a digital nomad visa for high-earning foreigners.



Over the last decade, the explosion of remote work that came as a result of improved technology and the pandemic has allowed an increasing number of people to become digital nomads. 

When looked at more broadly as anyone not required to come into a fixed office but instead moves between different locations such as the home and the coffee shop, the latest estimate shows that there were more than 35 million such workers in the world by the end of 2023 while over half of those come from the United States.

Related: There is a new list of cities that are best for digital nomads

While remote work has also allowed many to move to cheaper places and travel around the world while still bringing in income, working outside of one's home country requires either dual citizenship or work authorization — the global shift toward remote work has pushed many countries to launch specific digital nomad visas to boost their economies and bring in new residents.

Japan is a very popular destination for U.S. tourists. 


This popular vacation destination will soon have a nomad visa

Spain, Portugal, Indonesia, Malaysia, Costa Rica, Brazil, Latvia and Malta are some of the countries currently offering specific visas for foreigners who want to live there while bringing in income from abroad.

More Travel:

With the exception of a few, Asian countries generally have stricter immigration laws and were much slower to launch these types of visas that some of the countries with weaker economies had as far back as 2015. As first reported by the Japan Times, the country's Immigration Services Agency ended up making the leap toward a visa for those who can earn more than ¥10 million ($68,300 USD) with income from another country.

The Japanese government has not yet worked out the specifics of how long the visa will be valid for or how much it will cost — public comment on the proposal is being accepted throughout next week. 

That said, early reports say the visa will be shorter than the typical digital nomad option that allows foreigners to live in a country for several years. The visa will reportedly be valid for six months or slightly longer but still no more than a year — along with the ability to work, this allows some to stay beyond the 90-day tourist period typically afforded to those from countries with visa-free agreements.

'Not be given a residence card of residence certificate'

While one will be able to reapply for the visa after the time runs out, this can only be done by exiting the country and being away for six months before coming back again — becoming a permanent resident on the pathway to citizenship is an entirely different process with much more strict requirements.

"Those living in Japan with the digital nomad visa will not be given a residence card or a residence certificate, which provide access to certain government benefits," reports the news outlet. "The visa cannot be renewed and must be reapplied for, with this only possible six months after leaving the countr

The visa will reportedly start in March and also allow holders to bring their spouses and families with them. To start using the visa, holders will also need to purchase private health insurance from their home country while taxes on any money one earns will also need to be paid through one's home country.

Read More

Continue Reading